Advisors Asset Management’s Acceleron Pharma XLRN Stock Holding History

Advisors Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,073	Closed	-$2.08M	–	1543
2021 Q3	$2.08M	Buy	12,073 +471	+4%	+$61.6K	0.03%	577
2021 Q2	$1.46M	Buy	11,602 +2,896	+33%	+$365K	0.02%	697
2021 Q1	$1.18M	Buy	8,706 +3,350	+63%	+$433K	0.02%	773
2020 Q4	$685K	Buy	5,356 +3,400	+174%	+$399K	0.01%	885
2020 Q3	$220K	Buy	1,956 +906	+86%	+$90.2K	﹤0.01%	1153
2020 Q2	$100K	Buy	+1,050	New	+$101K	﹤0.01%	1305

Advisors Asset Management's XLRN Position: Q4 2021 in Review

Advisors Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 12,073 shares — an estimated $2.08M sold.

Advisors Asset Management first reported a position in XLRN in Q2 2020 and held it in 6 quarters. The position peaked at $2.08M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Advisors Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Advisors Asset Management sold 12,073 Acceleron Pharma shares in Q4 2021, an estimated $2.08M.
Advisors Asset Management first reported a position in Acceleron Pharma in Q2 2020 and held it in 6 quarters.
Advisors Asset Management's Acceleron Pharma position peaked at $2.08M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Advisors Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.